Optune Pax Patient Usage Declines in Q3 2026

The number of active patients using the device fell as the company adjusted its outreach tactics.

Updated on Oct. 29, 2026 in Cancer

Isometric editorial illustration of a sculptural medical device array on a clinical plinth, representing cancer treatment market shifts. — Novocure reported that active U.S. patient usage of its Optune Pax cancer device fell to 266 in the third quarter of 2026. AI Illustration. Upload story photo >

Live Poll

Do you believe new pharmaceutical drug launches inevitably disrupt established medical device markets?

Novocure reported that active U.S. patient usage of its Optune Pax cancer treatment fell from 285 in the second quarter of 2026 to 266 in the third quarter of 2026. This decline occurred as the company expanded its financial outlook for the full year.

Why it matters

The company cited the August 2026 FDA approval of Daraxonrasib as a factor influencing its access to medical practices, which may affect clinical adoption patterns. Ongoing market shifts like this are important for patients monitoring treatment availability.

Novocure reported a drop in patient usage of Optune Pax to 266 individuals in the third quarter of 2026, compared to 285 in the prior quarter. It remains unknown how the company’s planned tactical shifts will influence future patient engagement.

The players

Novocure

A medical device company that develops electrical field-based treatments for cancer.

The details

Optune Pax, which received FDA approval in February 2026, uses electrical fields to disrupt the division of cancer cells. The company reported that the introduction of new competing therapies has impacted its ability to maintain share of voice in medical settings. Novocure currently plans to adjust its outreach tactics to address these access challenges.

February 2026: Optune Pax received FDA approval.
Q2 2026: Optune Pax had 285 active U.S. patients.
August 26, 2026: Daraxonrasib received FDA approval.
Q3 2026: Optune Pax active U.S. patients declined to 266.
September 30, 2026: Novocure reported $463.5 million in cash.

Health Landscape

The market adoption of Optune Pax reflects broader trends in the competitive oncology device landscape. These figures provide a baseline for observing how novel electrical field therapies integrate alongside new pharmaceutical competitors.

Patients and caregivers should be aware that market availability and practice access for specific cancer treatments can fluctuate following new drug approvals. It is worth discussing current treatment options and access with your physician to ensure continuity of care.

The takeaway

Healthcare markets are dynamic, and the recent decline in Optune Pax usage highlights the influence that new drug approvals can have on treatment access. Monitor changes in your care plan with your medical team to stay informed on the most effective options.